Current status of agents active against the T315I chronic myeloid leukemia phenotype

Expert Opinion on Emerging Drugs

Volumn 16, Issue 1, 2011, Pages 85-103

  Burke, Aine Carol ^a   Swords, Ronan T ^b   Kelly, Kevin ^b   Giles, Francis J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

chronic myeloid leukemia; drug development; imatinib resistance; T315I

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ADAPHOSTIN; AG 957; ALVESPIMYCIN; AP 24163; AP 24534; AS 703569; AURORA KINASE INHIBITOR; BAG 956; BCR ABL PROTEIN; BO 1; BORTEZOMIB; BOSUTINIB; CP 2005; DACINOSTAT; DANUSERTIB; DASATINIB; DCC 2036; DCC 2157; DORAMAPIMOD; DP 2494; DP 2629; EVEROLIMUS; GNF 2; GNF 5; GSK 1120212; IMATINIB; INTERFERON; ISOLEUCINE; KW 2449; LONAFARNIB; LY 29402; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MLN 8237; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NILOTINIB; NSC 654705; NVPAUY 922; NVPBEZ 235; ON 044580; ON 044690; ON 045260; PANOBINOSTAT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; RIDAFOROLIMUS; ROMIDEPSIN; SGX 393; SGX 70393; SORAFENIB; TANESPIMYCIN; TEMSIROLIMUS; TG 100598; TG 101113; TG 101477; THREONINE; TIPIFARNIB; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 456; WP 1130; XL 228;

ALLOSTERISM; AMINO ACID SUBSTITUTION; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOGENETICS; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; HUMAN; IC 50; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 79952141077     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.531698     Document Type: Review

References (206)

1. Surveillance EaERP. SEER Stat Fact Sheets. 2010 [Cited].Available from: http://seer.cancer.gov/csr/1975-2007/results-single/sect-01-table.01.pdf
2. Nowell P, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;142:1497
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944):824-30
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;16(10):3343-56
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004 (Pubitemid 36302244) (Pubitemid 36302244)
6. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111(3):1039-43 (Pubitemid 351213381) (Pubitemid 351213381)
7. O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of interferon versus STI571 (IRIS) 7-year Follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). ASH Annu Meeting Abstracts 2008;112(11):186
8. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009 2009;114(22):1126-
9. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd Trial. Blood (ASH Annual Meeting Abstracts);2009;114(22):LBA-1
10. Gambacorti-Passerini C. Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. Haematologica 2006;91(2):145a
11. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20(10):1767-73 (Pubitemid 44574988) (Pubitemid 44574988)
12. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108(6):1809-20 (Pubitemid 44394987) (Pubitemid 44394987)
13. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984;63(4):789-99 (Pubitemid 14141296) (Pubitemid 14141296)
14. Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009;27(22):3642-9
15. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16(11):2190-6 (Pubitemid 35331833) (Pubitemid 35331833)
16. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on chronic myeloid leukemia. Clin Cancer Res 2006;12(24):7374-9 (Pubitemid 46095411) (Pubitemid 46095411)
17. Azam M, Shakespeare WC, Sawyer TK, Daley GQ. Targeted inhibition of Gatekeeper variant 'T315I' of BCR-ABL by a purine based ATP-competitive inhibitor. AACR Meeting Abstracts 2006;2006(1):1139-b
18. Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, et al. ERK2, but not ERK1, mediates acquired and 'de novo' resistance to imatinib mesylate: implication for CML therapy. PLoS One 2009;4(7):e6124
19. Dai Y, Rahmani M, Corey SJ, et al. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279(33):34227-39 (Pubitemid 39318046) (Pubitemid 39318046)
20. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101(2):690-8 (Pubitemid 36077594) (Pubitemid 36077594)
21. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64(2):672-7 (Pubitemid 38120909) (Pubitemid 38120909)
22. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18(3):401-8 (Pubitemid 38425851) (Pubitemid 38425851)
23. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99(9):3472-5 (Pubitemid 34525335) (Pubitemid 34525335)
24. Chien JH, Tang JL, Chen RL, et al. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leuk Res 2008;32(11):1724-34
25. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80 (Pubitemid 32743979) (Pubitemid 32743979)
26. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99(5):1860-2 (Pubitemid 34533064) (Pubitemid 34533064)
27. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102(1):276-83 (Pubitemid 36759665) (Pubitemid 36759665)
28. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359(9305):487-91 (Pubitemid 34164296) (Pubitemid 34164296)
29. Pricl S, Fermeglia M, Ferrone M, Tamborini E. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol Cancer Ther 2005;4(8):1167-74 (Pubitemid 41149564) (Pubitemid 41149564)
30. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004;5(1):55-60 (Pubitemid 38262791) (Pubitemid 38262791)
31. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcome of patients with chronic myeloid leukemia (CML) and T315I mutation following failure of imatinib mesylate therapy. ASH Annu Meeting Abstracts 2007;110(11):1943
32. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108(7):2332-8 (Pubitemid 44497517) (Pubitemid 44497517)
33. Nicolini FE, Bachy E, Corm S, et al. Clinical outcome of 27 imatinib mesylate resistant chronic myelogenous leukemia (CML) patients harbouring a T315I BCR-ABL mutation. ASH Annu Meeting Abstracts 2006;108(11):2190
34. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008;112(10):3965-73
35. Deciphera Pharmaceuticals. Bcr-Abl Programme. 2009 [cited]. Available from: http://www.deciphera.com/BCRABL. html
36. Van Etten RA, Chan WW, Zaleskas VM, et al. DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. ASH Annu Meeting Abstracts 2007;110(11):463
37. Van Etten RA, Chan WW, Zaleskas VM, et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I. ASH Annu Meeting Abstracts 2008;112(11):576
38. Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008;14(14):4392-9
39. Reddy EP. A non-ATP competitive inhibitor of BCR-ABL for the therapy of imatinib-resistant CML. Temple University, Philadelphia, PA; 2008
40. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2(2):95-102
41. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102(6):1992-7 (Pubitemid 40262000) (Pubitemid 40262000)
42. Donato NJ, Wu J, Bornmann W, Talpaz M. Activity of ABL kinase inhibitors in two distinct models of imatinib resistance. Blood (ASH Annual Meeting Abstracts) 2006;108(11):4819
43. Jatiani SS, Pallela SCCR, Ha JH, et al. Identification of a dual JAK-2/BCR-ABL kinase inhibitor for treatment of myeloproliferative disorders. 2009 AACR Annu Meeting 2009: abstract 3717
44. Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010;463(7280):501-6
45. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004;301(1):60-7 (Pubitemid 39388897) (Pubitemid 39388897)
46. Bergstrom DA, Clark JB, Xiao A, et al. MK-0457, a novel multikinase inhibitor, inhibits BCR-ABL activity in patients with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) with the T315I BCR-ABL mutation. ASH Annu Meeting Abstracts 2006;108(11):637
47. Seitz AK, von Bubnoff N, Sarno SM, et al. Activity of serono-AS703569, a dual inhibitor of Bcr-Abl and aurora kinases in Bcr-Abl transformed Cells, is dependent on aurora B inhibition, and is not affected by the presence of the highly imatinib resistant Bcr-Abl mutation T315I. Blood (ASH Annual Meeting Abstracts) 2009;114(22):3247
48. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007;251(2):323-9 (Pubitemid 46669805) (Pubitemid 46669805)
49. Giles FJ, Cortes J, Jones D, et al. MK- 0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109(2):500-2 (Pubitemid 46105945) (Pubitemid 46105945)
50. Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate. ASH Annu Meeting Abstracts 2007;110(11):1041
51. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112(5):1886-93
52. Nawrocki ST, Medina E, Smith S, et al. The aurora kinase inhibitor MLN8237 has potent anticancer activity in CML and Ph+ ALL models and significantly increases the efficacy of nilotinib. ASH Annu Meeting Abstracts 2008;112(11):3198
53. Shah NP, Kasap C, Paquette R, et al. Targeting Ddug-resistant CML and Ph +-ALL with the spectrum selective protein kinase inhibitor XL228. ASH Annu Meeting Abstracts 2007;110(11):474
54. Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation. ASH Annu Meeting Abstracts 2008;112(11):3232
55. Smith DC, Britten C, Clary DO, et al. A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 2009;27(15s)
56. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49(24):7247-51 (Pubitemid 44886012) (Pubitemid 44886012)
57. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008;111(8):4355-64
58. Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67(17):7987-90 (Pubitemid 47395130) (Pubitemid 47395130)
59. Balabanov S, Gontarewicz A, Keller G, et al. Combination therapy of small molecule inhibitor PHA-739358 and tyrosine kinase inhibitor imatinib yields synergistic antiproliferative effects and suppresses emergence of resistance of chronic myeloid leukemia in vitro. ASH Annu Meeting Abstracts 2008;112(11):3227
60. Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib Hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2009;114(22):864
61. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114(8):1607-17
62. Shiotsu Y, Kiyoi H, Ozeki K, et al. KW-2449, a novel multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora, suppresses the growth of AML both in vitro and in vivo. ASH Annu Meeting Abstracts 2007;110(11):1832
63. Pratz KW, Stine A, Karp J, et al. Optimizing the dose and schedule of KW-2449, FLT3/aurora inhibitor, through analysis of in vivo target inhibition. J Clin Oncol 2008;26(20 Suppl):abstract 7069
64. Tanaka R, Squires MS, Kimura S, et al. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 2010;116(12):2089-95
65. Squires MS, Curry JE, Dawson MA, et al. AT9283, a potent inhibitor of JAK2, is active in JAK2 V617F myeloproliferative disease models. ASH Annu Meeting Abstracts 2007;110(11):3537
66. Foran J, Ravandi F, O'Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2008;26(May 20 Suppl):abstract 2518
67. Akahane D, Tauchi T, Okabe S, et al. Activity of a novel aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci 2008;99(6):1251-7 (Pubitemid 351676639) (Pubitemid 351676639)
68. Schenone S, Brullo C, Musumeci F, Botta M. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs 2010;19(8):931-45
69. Crespan E, Radi M, Zanoli S, et al. Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms. Bioorg Med Chem 2010;18(11):3999-4008
70. Huang KH, Veal JM, Fadden RP, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 2009;52(14):4288-305
71. O'Hare T, Pollock R, Stoffregen EP, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004;104(8):2532-9 (Pubitemid 39331857) (Pubitemid 39331857)
72. Azam M, Nardi V, Shakespeare WC, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103(24):9244-9 (Pubitemid 43902563) (Pubitemid 43902563)
73. Azam M, Powers JT, Einhorn W, et al. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des 2010;75(2):223-7
74. Shakespeare WC, Wang F, Xu Q, et al. Orally active inhibitors of the imatinib resistant Bcr-Abl mutant T315I. ASH Annu Meeting Abstracts 2006 ;108(11):2180
75. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16(5):401-12
76. O'Hare T, Eide CA, Adrian LT, et al. Complete suppression of in vitro resistance by AP24534, a pan-BCR-ABL inhibitor. ASH Annu Meeting Abstracts 2008;112(11):726
77. Rivera VM, Xu Q, Wang F, et al. Potent antitumor activity of AP24534, an orally active inhibitor of Bcr-Abl variants including T315I, in in vitro and in vivo models of chronic myeloid leukemia (CML). ASH Annu Meeting Abstracts 2007;110(11):1032
78. Cortes J, Talpaz M, Deininger M, et al. A Phase 1 Trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. Blood (ASH Annual Meeting Abstracts) 2009;114(22):643
79. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4- methylpiperazin-1-y l)methyl]-3- (trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53(12):4701-19
80. Zhu H. Enzymatic and cellular inhibition of BCR/ABLT315I by a novel src/ABL inhibitor. AACR Meeting Abstracts 2006;2006(1):887-a
81. Zhu H. Addressing BCR/Abl resistance: evolving dasatinib to an novel inhibitor of the T315I BCR/Abl mutation. AACR Meeting Abstracts 2007;2007(1-Annual-Meeting):3254
82. Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T3151 mutation. Curr Top Med Chem 2008;8(10):905-21
83. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988;242(4880):933-5 (Pubitemid 19015255) (Pubitemid 19015255)
84. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. Faseb J 1992;6(14):3275-82
85. Svingen PA, Tefferi A, Kottke TJ, et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000;6(1):237-49 (Pubitemid 30064999) (Pubitemid 30064999)
86. Chandra J, Hackbarth J, Le S, et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003;102(13):4512-19 (Pubitemid 37494118) (Pubitemid 37494118)
87. Mow BM, Chandra J, Svingen PA, et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002;99(2):664-71 (Pubitemid 34533106) (Pubitemid 34533106)
88. Le SB, Hailer MK, Buhrow S, et al. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 2007;282(12):8860-72 (Pubitemid 47093495) (Pubitemid 47093495)
89. Long J, Manchandia T, Ban K, et al. Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. Cancer Chemother Pharmacol 2007;59(4):527-35 (Pubitemid 46122331) (Pubitemid 46122331)
90. Li M, Wang H, Hill DL, et al. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Cancer Chemother Pharmacol 2006;57(5):607-14 (Pubitemid 43237845) (Pubitemid 43237845)
91. O'Hare T, Eide CA, Tyner JW, et al. Inhibition of T315I Bcr-Abl and other imatinib-resistant Bcr-Abl mutants by the selective Abl kinase inhibitor SGX70393. ASH Annu Meeting Abstracts 2006;108(11):1373
92. O'Hare T, Eide CA, Tyner JW, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 2008;105(14):5507-12 (Pubitemid 351753893) (Pubitemid 351753893)
93. Regan J, Breitfelder S, Cirillo P, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002;45(14):2994-3008 (Pubitemid 34721521) (Pubitemid 34721521)
94. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36 (Pubitemid 41094421) (Pubitemid 41094421)
95. O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 2005;23(10):1209-10, author reply 10-1
96. Fabian MA, Biggs WH, Treiber DK, et al. Reply to BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotech 2005;23(10):1210-11
97. Choi HG, Ren P, Adrian F, et al. A type-II kinase inhibitor capable of inhibiting the T315I 'Gatekeeper' mutant of Bcr-Abl. J Med Chem 2010
98. Weisberg E, Choi HG, Ray A, et al. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 2010;115(21):4206-16
99. Alvarado Y, Giles FJ. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 2007;12(2):271-84 (Pubitemid 46953566) (Pubitemid 46953566)
100. Tamanoi F, Kato-Stankiewicz J, Jiang C, et al. Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl 2001;(Suppl 37):64-70
101. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001;97(5):1404-12 (Pubitemid 32183766) (Pubitemid 32183766)
102. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 2001;97(5):1399-403 (Pubitemid 32183765) (Pubitemid 32183765)
103. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100(3):1068-71 (Pubitemid 34832641) (Pubitemid 34832641)
104. Nakajima A, Tauchi T, Sumi M, et al. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther 2003;2(3):219-24
105. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97(11):3361-9
106. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101(5):1692-7 (Pubitemid 36237561) (Pubitemid 36237561)
107. Cortes J, Quintas-Cardama A, Garcia-Manero G, et al. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007;110(9):2000-6 (Pubitemid 350036859) (Pubitemid 350036859)
108. Jorgensen HG, Allan EK, Graham SM, et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005;19(7):1184-91 (Pubitemid 40946002) (Pubitemid 40946002)
109. Cortes J, Jabbour E, Daley GQ, et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007;110(6):1295-302 (Pubitemid 47435601) (Pubitemid 47435601)
110. Borthakur G, Kantarjian H, Daley G, et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006;106(2):346-52 (Pubitemid 43100443) (Pubitemid 43100443)
111. Hunt JT, Ding CZ, Batorsky R, et al. Discovery of (R)-7-cyano-2,3,4, 5- tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)- 1H- 1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem 2000;43(20):3587-95
112. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111(5):2843-53
113. Lee FY, Wen M-L, Camuso A, et al. Quiescent chronic myelogenous leukemia (CML) cells are resistant to BCR-ABL inhibitors but preferentially sensitive to BMS-214662, a farnesyltransferase inhibitor (FTI) with unique quiescent-cell selective cytotoxicity. Blood (ASH Annual Meeting Abstracts) 2005;106(11):1993
114. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007;72(3):788-95 (Pubitemid 47351213) (Pubitemid 47351213)
115. Dasmahapatra G, Yerram N, Dai Y, et al. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 2007;13(14):4280-90 (Pubitemid 47108172) (Pubitemid 47108172)
116. Kurosu T, Ohki M, Wu N, et al. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res 2009;69(9):3927-36
117. Alessi DR, Cuenda A, Cohen P, et al. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270(46):27489-94
118. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273(29):18623-32 (Pubitemid 28334795) (Pubitemid 28334795)
119. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5(7):810-16 (Pubitemid 29318616) (Pubitemid 29318616)
120. Nguyen TK, Rahmani M, Gao N, et al. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res 2006;12(7 Pt 1):2239-47
121. Nguyen TK, Rahmani M, Harada H, et al. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007;109(9):4006-15 (Pubitemid 46641754) (Pubitemid 46641754)
122. Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 2005;19(9):1579-89 (Pubitemid 43090402) (Pubitemid 43090402)
123. Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002;62(1):188-99 (Pubitemid 34074004) (Pubitemid 34074004)
124. Lunghi P, Mazzera L, Corradi A, et al. Arsenic trioxide (ATO) interacts synergistically with MEK inhibitors to induce apoptosis in STI571-resistant Bcr-Abl mutants. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2177
125. Berger DM, Mallon R. Kinase components of the Ras-MAPK signaling cascade as potential targets for therapeutic intervention. Drugs Future 2003;28(12)
126. Thompson DS, Flaherty K, Messersmith W, et al. A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. J Clin Oncol (Meeting Abstracts) 2009;27(15S):e14584
127. Ly C, Arechiga AF, Melo JV, et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63(18):5716-22 (Pubitemid 37187466) (Pubitemid 37187466)
128. Mayerhofer M, Valent P, Sperr WR, et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100(10):3767-75 (Pubitemid 35303950) (Pubitemid 35303950)
129. Elit L. Drug evaluation: AP-23573-an mTOR inhibitor for the treatment of cancer. IDrugs 2006;9(9):636-44 (Pubitemid 44382782) (Pubitemid 44382782)
130. Hartford CM, Desai AA, Janisch L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009;15(4):1428-34
131. Sillaber C, Mayerhofer M, Bohm A, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008;38(1):43-52 (Pubitemid 350293855) (Pubitemid 350293855)
132. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res 2009;33(3):450-9
133. Minami Y, Minami M, Kuwatsuka Y, et al. Treatment with mTOR inhibitor, everolimus (RAD001) overcomes resistance to imatinib in Ph-leukemia quiescent or T315I-mutated cells. Blood (ASH Annual Meeting Abstracts) 2009;114(22):3277
134. Mancini M, Corradi V, Petta S, et al. mTOR inhibitor RAD001 (Everolimus)
135. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005;19(10):1774-82 (Pubitemid 41486155) (Pubitemid 41486155)
136. Dong S, Kang S, Lonial S, et al. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 2008;22(3):572-7 (Pubitemid 351386727) (Pubitemid 351386727)
137. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005;2(3):150-7 (Pubitemid 40823166) (Pubitemid 40823166)
138. Yu C, Subler M, Rahmani M, et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003;2(5):544-51
139. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005;15(1):169-72
140. Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy 2007;3(5):464-7 (Pubitemid 47293728) (Pubitemid 47293728)
141. Carew JS, Nawrocki ST, Giles FJ, Cleveland JL. Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2008;2(2):201-4
142. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007;110(1):313-22 (Pubitemid 47026849) (Pubitemid 47026849)
143. Ertmer A, Huber V, Gilch S, et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007;21(5):936-42 (Pubitemid 46672069) (Pubitemid 46672069)
144. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119(5):1109-23
145. Mishima Y, Mishima Y, Terui Y, et al. An autophagy inhibitor, chloroquine, overcomes an imatinib-resistant T315I mutant of Bcr/Abl, whose latent may exist before imatinib treatment. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2183
146. Fiskus W, Bali P, Pranpat M, et al. Co-treatment with a novel heat shock protein (hsp) 90 inhibitor IPI504 and the histone deacetylase inhibitor (HDI) vorinostat (suberoylanilide hydroxamic acid, SAHA): a highly active combination against wild type or mutant Bcr-Abl-T315I or FLT-3-ITD-containing human leukemia cells. Blood (ASH Annual Meeting Abstracts) 2005;106(11):4461
147. Fiskus W, Pranpat M, Balasis M, et al. Co-treatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS- 354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006;12(19):5869-78 (Pubitemid 44629620) (Pubitemid 44629620)
148. Rahmani M, Reese E, Dai Y, et al. Co-treatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol 2005;67(4):1166-76 (Pubitemid 40416722) (Pubitemid 40416722)
149. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102(10):3765-74 (Pubitemid 37409399) (Pubitemid 37409399)
150. Dedes KJ, Dedes I, Imesch P, et al. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009;20(5):321-33
151. Okabe S, Tauchi T, Nakajima A, et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABLexpressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007;16(3):503-14 (Pubitemid 47016235) (Pubitemid 47016235)
152. Kawano T, Horiguchi-Yamada J, Iwase S, et al. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res 2004;24(5A):2705-12 (Pubitemid 39407146) (Pubitemid 39407146)
153. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280(2):233-41
154. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15(12):3958-69
155. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105(4):1768-76 (Pubitemid 40223701) (Pubitemid 40223701)
156. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006;108(2):645-52 (Pubitemid 44061366) (Pubitemid 44061366)
157. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63(16):5126-35 (Pubitemid 37022654) (Pubitemid 37022654)
158. Strauss AC, Chu S, Holyoake T, Bhatia R. Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib. Blood (ASH Annual Meeting Abstracts) 2007;110(11):1031
159. Calabretta B, Skorski T. BCR/ABL regulation of PI-3 kinase activity. Leuk lymphoma 1996;23(5-6):473-6 (Pubitemid 27029658) (Pubitemid 27029658)
160. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8(3):187-98 (Pubitemid 351688437) (Pubitemid 351688437)
161. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86(2):726-36
162. Marley SB, Lewis JL, Schneider H, et al. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol 2004;125(4):500-11 (Pubitemid 38916196) (Pubitemid 38916196)
163. Klejman A, Rushen L, Morrione A, et al. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002;21(38):5868-76 (Pubitemid 35007237) (Pubitemid 35007237)
164. Maslak PG, Krug L, Chanel S, et al. Pilot Study of a Wilms tumor protein (WT1) heteroclitic peptide vaccine in patients with myeloid and thoracic neoplasms. ASH Annu Meeting Abstracts 2007;110(11):903
165. Tseng PH, Lin HP, Zhu J, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase- 1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005;105(10):4021-7 (Pubitemid 40656151) (Pubitemid 40656151)
166. Okabe S, Tauchi T, Kimura S, et al. The efficacy of dual PI3K and mTOR inhibitor, NVP-BEZ235 against BCR-ABL positive leukemia cells include ABL kinase domain mutation in combination with nilotinib. Blood (ASH Annual Meeting Abstracts) 2009;114(22):3784
167. Bartholomeusz G, Talpaz M, Bornmann W, et al. Degrasyn activates proteasomal-dependent degradation of c-Myc. Cancer Res 2007;67(8):3912-18 (Pubitemid 46762180) (Pubitemid 46762180)
168. Donato N, Kapuria V, Sun H, et al. Degrasyn-induced trafficking of BCR-ABL as a novel mechanism of kinase inactivation. Blood (ASH Annu Meeting Abstracts) 2007;110(11):1003
169. Kapuria V, Bartholomeusz G, Kong L-Y, et al. A novel small-molecule approach to inhibit Jak2 tyrosine kinase signaling. ASH Annu Meeting Abstracts 2007;110(11):1556
170. Bartholomeusz GA, Talpaz M, Kapuria V, et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007;109(8):3470-8 (Pubitemid 46572537) (Pubitemid 46572537)
171. Donato NJ, Sun H, Kapuria V, et al. WP1130 Inhibits signaling through BCR-ABL ubiquitination and cytoplasmic to aggresome trafficking to induce apoptosis of CML cells. Blood (ASH Annual Meeting Abstracts) 2009;114(22):3303
172. Peterson LF, Sun H, Bornmann W, et al. Degrasyn (a novel tyrophostin) impacts BCR-ABL protein level and is cytotoxic to chronic myeloid leukemia early progenitors. Blood (ASH Annual Meeting Abstracts) 2008;112(11):3212
173. Gorre ME, Ellwood-Yen K, Chiosis G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002;100(8):3041-4
174. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 1970;23(9):442-7
175. Veuger MJ, Honders MW, Landegent JE, et al. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000;96(4):1517-24 (Pubitemid 30658485) (Pubitemid 30658485)
176. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17- demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61(5):1799-804 (Pubitemid 32691987) (Pubitemid 32691987)
177. Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001;15(10):1537-43 (Pubitemid 32994672) (Pubitemid 32994672)
178. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280(29):26729-34 (Pubitemid 41040705) (Pubitemid 41040705)
179. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;49(1):7-19
180. Peng C, Brain J, Hu Y, et al. Hsp-90 inhibition decreases survival of BCR-ABL T315I leukemic stem cells in mice. ASH Annu Meeting Abstracts 2006;108(11):2184
181. Peng C, Brain J, Hu Y, et al. IPI-504, a novel, orally active HSP90 inhibitor, prolongs survival of mice with BCR-ABL T315I CML and B-ALL. ASH Annu Meeting Abstracts 2006;108(11):2183
182. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs 2009;18(9):1375-83
183. Tauchi T, Okabe S, Ashihara E, et al. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Blood (ASH Annual Meeting Abstracts) 2009;114(22):3765
184. Mayerhofer M, Florian S, Krauth MT, et al. Identification of heme oxygenase-1 as a novel BCR/ABLdependent survival factor in chronic myeloid leukemia. Cancer Res 2004;64(9):3148-54 (Pubitemid 38581416) (Pubitemid 38581416)
185. Mayerhofer M, Aichberger KJ, Florian S, et al. The heme oxygenase-1-targeting compound PEG-ZnPP inhibits growth of imatinib-resistant BCR/ABL-transformed cells. Blood (ASH Annual Meeting Abstracts) 2004;104(11):1986
186. Chakraborty PK, Mustafi SB, Ganguly S, et al. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70. Cancer Sci 2008;99(6):1109-16 (Pubitemid 351676621) (Pubitemid 351676621)
187. Pasquet J-M, Pocaly M, Lagarde V, et al. The proteome analysis of an imatinib-resistant cell line identifies changes in molecular chaperones such as heat shock proteins (Hsp): a possible new mechanism of imatinib resistance. Blood (ASH Annual Meeting Abstracts) 2004;104(11):1981
188. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65(22):10536-44 (Pubitemid 41743748) (Pubitemid 41743748)
189. Puissant A, Grosso S, Jacquel A, et al. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. Faseb J 2008;22(6):1894-904 (Pubitemid 351811466) (Pubitemid 351811466)
190. Hannon GJ. RNA interference. Nature 2002;418(6894):244-51 (Pubitemid 34773784) (Pubitemid 34773784)
191. Withey JM, Marley SB, Kaeda J, et al. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 2005;129(3):377-80 (Pubitemid 40646897) (Pubitemid 40646897)
192. McLaughlin J, Cheng D, Singer O, et al. Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc Natl Acad Sci USA 2007;104(51):20501-6
193. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999;1489(1):31-44
194. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1994;91(10):4504-8
195. Larsen HJ, Bentin T, Nielsen PE. Antisense properties of peptide nucleic acid. Biochim Biophys Acta 1999;1489(1):159-66
196. Rapozzi V, Burm BE, Cogoi S, et al. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res 2002;30(17):3712-21 (Pubitemid 35012443) (Pubitemid 35012443)
197. Snyder DS, Wu Y, Wang JL, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 1993;82(2):600-5 (Pubitemid 23206127) (Pubitemid 23206127)
198. Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 2010;95(3):388-97
199. Cortes-Franco J, Khoury HJ, Nicolini FE, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr- Abl T315I mutation-results of an ongoing multicenter phase 2/3 Study. Blood (ASH Annual Meeting Abstracts) 2009;114(22):644
200. Ayoubi M, Kantarjian HM, Wierda W, et al. A Phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2193
201. Rongzhen X, Qinghua D, Yingzi Y, et al. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 2006;30(1):17-23
202. Wei YL, Liang Y, Xu L, Zhao XY. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Anat Rec (Hoboken) 2009;292(7):945-50
203. Lu Z, Jin Y, Qiu L, et al. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 2010;290(2)
204. Bright SA, McElligott AM, O'Connell JW, et al. Novel pyrrolo-1,5- benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer 2010;102(10):1474-82
205. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 2009;84(2):161-9
206. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-51